Effect of fetal diagnosis on the outcomes of second-trimester pregnancy termination for fetal abnormalities: A pilot study

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 21, Issue 8, 2008, Pages 523-527

  Lo, T K ^a   Lau, W L ^a   Lai, F K ^a   Lam, H S W ^a   Tse, H Y ^a   Leung, W C ^a   Chin, R K H ^a  

^a KWONG WAH HOSPITAL   (Hong Kong)

Author keywords

Fetal abnormality; Fetal diagnosis; Outcomes; Second trimester; Termination of pregnancy

Indexed keywords

ERGOMETRINE PLUS OXYTOCIN; HEMOGLOBIN; METOCLOPRAMIDE; MISOPROSTOL; OXYTOCIN;

ABORTION; ARTICLE; BODY MASS; CESAREAN SECTION; CONFIDENCE INTERVAL; FEMALE; FETUS DISEASE; FETUS HYDROPS; HUMAN; INCOMPLETE ABORTION; MAJOR CLINICAL STUDY; MATERNAL AGE; OUTCOME ASSESSMENT; PARITY; PILOT STUDY; PREGNANCY; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SECOND TRIMESTER PREGNANCY; STATISTICAL SIGNIFICANCE; TRISOMY 18; TRISOMY 21;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTION, EUGENIC; ADMINISTRATION, INTRAVAGINAL; ADULT; ALPHA-THALASSEMIA; CHROMOSOMES, HUMAN, PAIR 18; DOWN SYNDROME; FEMALE; FETUS; HEMOGLOBINS, ABNORMAL; HUMANS; MISOPROSTOL; PILOT PROJECTS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TRISOMY;

EID: 49749097941     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050802104835     Document Type: Article

References (20)

1. Hinshaw K, El-Refaey H, Rispin R, Templeton A. Midtrimester termination for fetal abnormality: Advantages of a new regimen using mifepristone and misoprostol. BJOG 1995;102:559-560.
2. Lalitkumar S, Bygdeman M, Gemzell-Danielsson K. Midtrimester induced abortion: A review. Hum Reprod Update 2007;13:37-52.
3. Induction of labour. Evidence-based Guidelines No. 9. London: Royal College of Obstetricians and Gynaecologists; 2001.
4. Dickinson JE, Evans SF. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet Gynecol 2003;101:1294-1299.
5. Ulreich S, Gruslin A, Nodell CG, Pretorius DH. Fetal hydrops and ascites. In: Nyberg DA, McGahan JP, Pretorius DH, Pilu G, editors. Diagnostic imaging of fetal anomalies. Philadelphia: Lippincott Williams & Wilkins; 2003. pp 713-744.
6. Dodd J, O'Brien L, Coffey J. Misoprostol for second and third trimester termination of pregnancy: A review of practice at the Women's and Children's Hospital, Adelaide, Australia. Aust N Z J Obstet Gynaecol 2005;45:25-29.
7. Verhulsdonk MT, Papatsonis DN, Heydanus R. Results of pregnancy termination for foetal congenital or chromosomal disorders or intrauterine foetal death by oral mifepristone and/or intravaginal misoprostol: Results of a retrospective study. [Article in Dutch] Ned Tijdschr Geneeskd 2007;151:815-820.
8. Dickinson JE, Godfrey ME, Evans SF. Efficacy of intravaginal misoprostol in second-trimester pregnancy termination: A randomised controlled trial. J Matern Fetal Med 1998;7:115-119.
9. Dickinson JE, Evans SF. The optimisation of intra-vaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am J Obstet Gynecol 2002;186:470-474.
10. Wilson RD, Chitayat D, McGillivray BC. Fetal ultrasound abnormalities: Correlation with fetal karyotype, autopsy findings, and postnatal outcome - five-year prospective study. Am J Med Genet 1992;44:586-590.
11. Vaknin Z, Ben-Ami I, Reish O, Herman A, Maymon R. Fetal abnormalities leading to termination of singleton pregnancy: The 7-year experience of a single medical centre. Prenat Diagn 2006;26:938-943.
12. Liao C, Wei J, Li Q, Li J, Li L, Li D. Nonimmune hydrops diagnosed during the second half of pregnancy in southern China. Fetal Diagn Ther 2007;22:302-305.
13. Wong KS, Ngai CS, Wong AY, Tang LC, Ho PC. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy. A randomised trial. Contraception 1998;59:207-210.
14. Wong KS, Ngai CS, Yeo EL, Tang LC, Ho PC. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: A randomised comparative trial. Hum Reprod 2000;15:709-712.
15. Tang OS, Thong KJ, Baird DT. Second trimester medical abortion with mifepristone and gemeprost: A review of 956 cases. Contraception 2001;64:29-32.
16. Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomized comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. Br J Obstet Gynaecol 2004;111:1001-1005.
17. Tang OS, Chan CCW, Kan ASY, Ho PC. A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation. Hum Reprod 2005;20:3062-3066.
18. Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation. Hum Reprod 2005;20:2348-54.
19. Goh SE, Thong KJ. Induction of second trimester abortion (12-20 weeks) with mifepristone and misoprostol: A review of 386 consecutive cases. Contraception 2006;73:516-519.
20. Sedan O, Golan A, Girtler O, Lurie S, Debby A, Sagiv R, Evron S, Glezerman M. Role of sonography in the diagnosis of retained product of conception. J Ultrasound Med 2004;23:371-374.